Radioiodine therapy

PreclinicalSmall molecule

FFabricio Lopes da Fonseca

Radioiodine therapy is one of 19 small molecule programs targeting Thyroid Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thyroid CarcinomaActive, not recruiting

Thyroid CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Thyroid Carcinoma

#DrugCompanyPhaseTrials

Lenvima

Mekinist

Cabometyx

Anlotinib Hydrochloride

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Approved

1 5

Nexavar

Bayer

Phase 2

4 6

Imjudo

AstraZeneca

Phase 2

1 7

Imfinzi

AstraZeneca

Phase 2

1 8

Gleevec

Novartis

Phase 2

1 9

Tafinlar

Novartis

Phase 2

1 10

Anlotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thyroid Carcinoma1 trial

Lacrimal Drainage System Obstruction Associated to Radioactive Iodine Therapy for Thyroid Carcinoma

Unknown status·FFabricio Lopes da Fonseca·N/A·NCT01579344·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Radioiodine therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Radioiodine therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Radioiodine therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fabricio Lopes da Fonseca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFabricio Lopes da Fonseca

Radioiodine therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thyroid Carcinoma1 trial

References

Drug Info

Quick Facts

Related News